profit from every $100 of sales.
$0$100
BillionToOne
$110.79+0.51% today
+0.7% in 1 year
1-year low $64.031-year high $149.97
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2023 to 2025.
0%20% a year
You pay $710.09 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BillionToOne sold, what it kept, and what it did with the cash.
Sales went from $71.7 million in 2023 to $305 million in 2025, with $7.45 million of profit last year.
SalesProfit
BillionToOne vs. similar companies
BillionToOne grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BillionToOne | 710.1× · Very expensive | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.2× · Expensive | ||
 Waters | 141.4× · Very expensive | ||
 WuXi AppTec | 27.1× · Fair price |
AI analysis
An AI analyst reads BillionToOne's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| 72 | 153 | 305 | |
| 17 | 81 | 208 | |
| -69 | -47 | 16 | |
| – | – | 20 | |
| -83 | -42 | 7 | |
| -8.45 | -4.12 | 0.14 | |
| 24.1% | 53.0% | 68.3% | |
| -96.9% | -30.9% | 5.3% | |
| -115.3% | -27.2% | 2.4% |
Balance sheet
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total assets | – | 302 | 633 |
| Cash | 97 | 191 | 496 |
| Total debt | – | 51 | 109 |
| Total liabilities | – | 134 | 153 |
| -219 | -252 | 480 | |
| 10 | 10 | 21 | |
| – | – | 1.1% | |
| 37.7% | 16.5% | 1.6% |
Cash flow
| In millions of USD | 2023 | 2024 | 2025 |
|---|---|---|---|
| -54 | -41 | 25 | |
| 6 | 5 | 9 | |
| -60 | -47 | 16 | |
| Dividends paid | – | – | – |
| 0 | 1 | 0 | |
| 5 | 8 | 16 |
Valuation
- 710.1×
- 233.6×
- –
- 11.1×
- 17.3×
- 337.7×
- 248.3×
- 0.3%
- 0.1%
- 0.0%
Profitability
- 68.3%
- 5.3%
- 2.4%
- 11.6%
- 1.1%
- 1.1%
- 7.6%
- 3.6%
- 5.6%
- 15.1%
Growth
- +106.2%
- –
- +133.6%
- –
- −31.1%
Financial health
- -19.6×
- 0.23
- 20.6%
- 82.7×
- 11.69
- 10.58
- 0.51
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 38%of 952
Bottom 39%of 883
Top 5%of 870
Bottom 42%of 985
What analysts expect
- Average price target
- $130.33
- Range
- $110.00 – $150.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.34 | 0.03 | +981.8% |
| Mar 4, 2026 | 0.11 | 0.06 | +82.7% |
| Dec 9, 2025 | 0.10 | 0.14 | −28.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
62Pass
Benjamin Graham
59No pass
Philip Fisher
55No pass
Peter Lynch
61Pass
Joel Greenblatt
0No pass
Charlie Munger
48No pass
Terry Smith
53No pass
Questions about BillionToOne
Is BillionToOne a good stock to buy?
A business with weak numbers, priced as if everything goes right. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BillionToOne AI analysis
What does BillionToOne do?
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It is in Diagnostics & Research, based in Menlo Park, CA, United States, with 713 employees.
Does BillionToOne pay a dividend?
No. BillionToOne does not pay a dividend at the moment.
Is BillionToOne stock halal?
Yes. BillionToOne passes our halal screen: its business is permitted and its debt is 2% of its market value, under the 30% limit. How we check
How has BillionToOne stock done over the past year?
Up 0.7% over the past twelve months, to $110.79. It traded between $64.03 and $149.97 and is 26.1% below its high.
Who are BillionToOne's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with BillionToOne's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.